secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2026-08-06T20:08:11+00:00
Accession:  0001628280-26-054288
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Q2 rev $28.5M (+21% YoY); GAAP net $45.1M incl $42.4M tax benefit; Repligen deal pending Q4
--------------------------------------------------------------------------------

- Total revenue $28.5M, up 21% YoY from $23.4M; GAAP gross margin 64%.
- GAAP net income $45.1M includes $42.4M non-cash tax benefit from valuation allowance release; adjusted net income $4.2M.
- Adjusted EBITDA $7.4M (26% of revenue) vs $5.6M (24%) in Q2 2025.
- On July 21, 2026, BioLife agreed to be acquired by Repligen for ~$1.5B enterprise value; expected close Q4 2026.
- Biopreservation media used in ~250 ongoing commercial CGT clinical trials (>70% market share); embedded in 18 approved therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828026054288/0001628280-26-054288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828026054288/blfs-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-054288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer